Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. (NASDAQ: TNON) is a medical device company focused on minimally invasive sacroiliac (SI) joint and sacro-pelvic fusion technologies. News about Tenon often centers on its Catamaran SI Joint Fusion System, the Catamaran SE reduced-profile implant, and the SImmetry and SImmetry+ SI Joint Fusion Systems acquired through the SiVantage transaction. These platforms are designed to stabilize the SI joint and promote true fusion using titanium implants and proprietary instrumentation.
Investors and clinicians following TNON news can expect updates on product clearances, commercial launches and clinical milestones. Recent announcements include FDA 510(k) clearance for the SImmetry+ SI Joint Fusion System, which uses 3D-printed titanium implants and a minimally invasive lateral access approach, and the successful completion of initial clinical cases with SImmetry+ at spine centers across multiple U.S. states. Tenon also reports on the full market launch of the Catamaran SE SI Joint Fusion System, expanding its implant portfolio with a smaller device option for varying anatomy and revision scenarios.
Tenon’s news flow also covers financial performance and capital markets activity. Quarterly earnings releases discuss revenue from Catamaran and SImmetry procedures, gross margin trends, operating expenses, and cash balances, as well as integration progress for acquired assets and commercial expansion. The company has announced at‑the‑market PIPE financings, detailed in both press releases and Form 8‑K filings, describing share and warrant issuances and intended use of proceeds for working capital, product launches, clinical studies and commercial operations.
Corporate updates in TNON news include asset purchase agreements for sacro-pelvic technologies, employment agreements with key commercial and innovation leaders, and governance matters such as annual meeting voting results and equity incentive plan amendments. For readers tracking developments in SI joint fusion devices, Tenon’s news page provides a centralized view of regulatory, clinical, commercial and financing events related to its sacro-pelvic fusion portfolio.
Tenon Medical (NASDAQ:TNON) reported record Q4 2025 revenue of $1.5M (up 92% YoY) and record full-year 2025 revenue of $3.9M (up 20% YoY). Gross profit was $1.0M in Q4 and $2.4M for 2025, with margins improving to 69% and 60% respectively.
The company secured FDA 510(k) clearance for SImmetry+ and completed initial procedures, closed a $2.85M ATM PIPE in Q4, and announced a subsequent $4.3M senior convertible note placement in March 2026.
Tenon Medical (NASDAQ:TNON) closed a private placement of senior original-issue-discount convertible notes, raising $4.3 million aggregate gross proceeds.
The 20% OID notes mature on September 11, 2026 and are convertible after six months into common stock at a conversion price equal to 80% of the 3-day VWAP prior to conversion. Net proceeds will fund commercial expansion, product development, clinical studies, working capital and general corporate purposes.
Tenon Medical (NASDAQ:TNON) closed a private placement of senior convertible notes for $4.3 million gross on March 12, 2026. The notes carry a 20% original issue discount, mature on September 11, 2026, and convert after six months at 80% of the 3‑day VWAP.
The company said net proceeds will fund commercial expansion, product development, clinical studies, working capital and general corporate purposes. Placement agent fees apply; notes and conversion shares are unregistered.
Tenon Medical (NASDAQ:TNON) announced a strategic expansion of its intellectual property portfolio on February 18, 2026, following USPTO Notices of Allowance for multiple patent applications expected to issue in 2026. The company reported a portfolio of 29 issued U.S. patents, 9 international patents, and 31 pending applications.
Tenon also cited its recent asset acquisition of SIVantage's SImmetry and SImmetry+ systems, supported by 16 issued U.S. patents, which the company says complements the Catamaran platform and strengthens protection for its sacro-pelvic fusion technologies.
Tenon Medical (NASDAQ:TNON) said it will report fourth quarter and full year 2025 results after market close on March 19, 2026 and host a conference call the same day at 4:30 p.m. ET. The company provided revenue ranges: Q4 2025 $1.45–$1.48M (~90% YoY) and FY2025 $3.91–$3.94M (~20% YoY). Dial‑in, international numbers, webcast details, and replay access through April 2, 2026 were provided, with telephone replay access code 13758268.
Tenon (NASDAQ:TNON) reported preliminary, unaudited Q4 2025 revenue of $1.45–$1.48 million (~90% YoY) and full year 2025 revenue of $3.91–$3.94 million (~20% YoY). The company highlighted the SiVantage acquisition, FDA clearance for an expanded Catamaran indication, strong MAINSAIL 12-month fusion results (83% fusion), and plans to report audited results in March 2026.
Tenon Medical (NASDAQ:TNON) announced completion of initial clinical procedures using its new SImmetry+ SI Joint Fusion System on December 4, 2025, with cases at Centers of Excellence in Florida, Arizona, Ohio, and Texas.
The minimally invasive lateral system uses 3D-printed titanium implants, joint decortication, and a bone graft delivery system, cleared for use with one to three implants. Tenon cites published 12-month EvoluSIon data (250 patients): 68.7% radiographic fusion at 12 months and a 57.1% decrease in pre-operative opioid use.
Tenon is conducting a controlled early-access rollout with select SI fusion physicians to gather procedural feedback ahead of broader commercial launch.
Tenon Medical (NASDAQ:TNON) announced the closing of an at-the-market PIPE financing on November 14, 2025 that generated approximately $2.85 million in gross proceeds.
The company issued 2,217,904 shares of common stock and issued warrants to purchase an equal number of shares; each share-plus-warrant was sold at a combined price of $1.285. The PIPE Warrants carry a $1.16 exercise price and expire three years from issuance. Proceeds are intended for working capital, upcoming product launches, commercial expansion, clinical studies, and general corporate purposes.
Tenon Medical (NASDAQ:TNON) reported Q3 2025 revenue of $1.2M, a 32% year-over-year increase driven by record Catamaran procedure volumes and the addition of SImmetry product sales. Gross profit was $773K with a 66% gross margin, up from 47% a year earlier. Q3 net loss was $3.3M (‑$0.40 per share). Cash and cash equivalents were $3.4M at September 30, 2025, and subsequent to quarter end the company raised $2.85M in PIPE financing. Tenon completed the SiVantage acquisition, expanded commercial training (26 physicians trained), and launched Catamaran SE and SImmetry+ activity to broaden its multi-product SI fusion portfolio.
Tenon Medical (NASDAQ:TNON) announced an at-the-market PIPE financing priced on November 11, 2025 to raise gross proceeds of $2,850,000. Under securities purchase agreements dated September 10, 2025, the company will issue 2,217,904 shares of common stock and warrants to purchase 2,217,904 shares at a combined offering price of $1.285 per share plus warrant. The PIPE warrants carry a $1.16 strike price and expire three years from issuance. The Issued Shares and warrant shares will have customary resale registration rights. Closing is subject to customary conditions. Tenon intends to use proceeds for working capital, product launches, commercial expansion, clinical studies, and core operations.